Lung Cancer Clinical Trials in Anaheim, CA

Lung Cancer Clinical Trials in Anaheim, CA

View the best 10 lung cancer medical studies in Anaheim, California. Access promising new therapies by applying to a Anaheim-based Lung Cancer clinical trial.

Trials in Anaheim, California

Here are the top 10 medical studies for lung cancer in Anaheim, California

Image of UCI Health Family Health Center - Anaheim in Anaheim, United States.

Empower Latinx

Behavioural Intervention

Recruiting1 award
This trial aims to improve lung cancer screening among Hispanic/Latinx individuals, who currently have limited access to healthcare services. The study will test a multi-level intervention that includes notifying primary care providers about patients
Image of CTCA at Western Regional Medical Center in Goodyear, United States.

Carboplatin +8 More

Platinum-based Chemotherapy

Recruiting1 awardPhase 2
This trial is studying a combination of biomarker/ALK inhibitors to treat patients with stage IV ALK positive non-squamous non-small cell lung cancer.
Image of Research Site - Orange City in Orange City, United States.

HLX10

Monoclonal Antibodies

Recruiting3 awardsPhase 3
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Image of Providence - Saint Joseph Home Health in Anaheim, United States.

Phase 3 comparator arm +3 More

Chemotherapy

Recruiting1 awardPhase 2 & 3
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Crizotinib

Tyrosine Kinase Inhibitor

Recruiting2 awardsPhase 3
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Image of Katmai Oncology Group in Anchorage, United States.

Carboplatin +4 More

Alkylating agents

Recruiting2 awardsPhase 3
This trial is testing the addition of the immunotherapy drug pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer.
Image of UC San Diego Moores Cancer Center in La Jolla, United States.

Amivantamab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug called Amivantamab alone and with other treatments in patients with advanced lung cancer that hasn't responded to other treatments. The goal is to see if these combinations are safe and effective. The drugs work by stopping cancer cells from growing. Amivantamab targets a rare lung cancer mutation that has been difficult to treat with existing medications.
Image of Research Site in Santa Rosa, United States.

MRTX849 (Adagrasib)

Small Molecule Drug

Recruiting2 awardsPhase 3
This trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Image of Research Site in Chandler, United States.

Docetaxel +2 More

Taxane

Recruiting3 awardsPhase 3
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Image of Research Site in Phoenix, United States.

Datopotamab Deruxtecan

Anti-tumor antibiotic

Recruiting2 awardsPhase 3
This trial is testing a new treatment called Dato-DXd along with rilvegostomig for patients with Stage I lung cancer who have had surgery to remove the tumor. The study will

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.